Table 2.
Clinicopathological Correlation of the Deletions Spanning the Pre-S2 Gene Segment in 40 HBV-Related HCC Patients
| Characteristicsa | Negative (No. of Patients (%)) | Positive (No. of Patients (%)) | P-valueb |
|---|---|---|---|
| Density of PD-1-positive cellsc | 19 (100) | 21 (100) | |
| high | 9 (47) | 10 (48) | 0.2482 |
| low | 10 (53) | 11 (52) | |
| Density of PD-L1-positive cellsd | 19 (100) | 21 (100) | |
| high | 2 (11) | 18 (86) | <0.0001*** |
| low | 17 (89) | 3 (14) | |
| Age (years) | 19 (100) | 21 (100) | |
| >50 | 16 (84) | 13 (62) | 0.0853 |
| ≤50 | 3 (16) | 8 (38) | |
| Gender | 19 (100) | 21 (100) | |
| men | 16 (84) | 18 (86) | 0.3358 |
| women | 3 (16) | 3 (14) | |
| Smoking | 19 (100) | 21 (100) | |
| yes | 7 (37) | 7 (33) | 0.2525 |
| no | 12 (63) | 14 (67) | |
| Alcohol | 19 (100) | 21 (100) | |
| yes | 2 (11) | 7 (33) | 0.0727 |
| no | 17 (89) | 14 (67) | |
| HBsAge | 17 (100) | 19 (100) | |
| positive | 17 (100) | 19 (100) | |
| negative | 0 (0) | 0 (0) | |
| HBeAg | 19 (100) | 21 (100) | |
| positive | 2 (11) | 4 (19) | 0.2666 |
| negative | 17 (89) | 17 (81) | |
| HBV genotype | 19 (100) | 21 (100) | |
| B | 15 (79) | 16 (76) | 0.2884 |
| C | 4 (21) | 5 (24) | |
| HBV DNA (copies/mL) | 18 (100) | 18 (100) | |
| >1×104 | 12 (67) | 12 (67) | 0.2753 |
| ≤1×104 | 6 (33) | 6 (33) | |
| Albumin (g/dL) | 19 (100) | 21 (100) | 0.0775 |
| >3.8 | 11 (58) | 7 (33) | |
| ≤3.8 | 8 (42) | 14 (67) | |
| AST (U/L) | 19 (100) | 21 (100) | |
| >34 | 17 (89) | 15 (71) | 0.1207 |
| ≤34 | 2 (11) | 6 (29) | |
| ALT (U/L) | 19 (100) | 21 (100) | |
| >40 | 13 (68) | 13 (62) | 0.2379 |
| ≤40 | 6 (32) | 8 (38) | |
| AFP (ng/mL) | 19 (100) | 21 (100) | |
| >400 | 5 (26) | 10 (48) | 0.1020 |
| ≤400 | 14 (74) | 11 (52) | |
| Tumor size (cm) | 19 (100) | 21 (100) | |
| >5 | 7 (37) | 7 (33) | 0.2525 |
| ≤5 | 12 (63) | 14 (67) | |
| Tumor encapsulation | 19 (100) | 20 (100) | |
| yes | 16 (84) | 14 (70) | 0.1772 |
| no | 3 (16) | 6 (30) | |
| Satellite nodule | 19 (100) | 21 (100) | |
| yes | 2 (11) | 5 (24) | 0.1866 |
| no | 17 (89) | 16 (76) | |
| Lymph node involvement | 19 (100) | 21 (100) | |
| yes | 4 (21) | 2 (10) | 0.2121 |
| no | 15 (79) | 19 (90) | |
| Portal vein thrombosis | 19 (100) | 21 (100) | |
| yes | 1 (5) | 0 (0) | 0.4750 |
| no | 18 (95) | 21 (100) | |
| Vascular invasion | 19 (100) | 21 (100) | |
| yes | 8 (42) | 10 (48) | 0.2351 |
| no | 11 (58) | 11 (52) | |
| Distant metastasis | 19 (100) | 21 (100) | |
| yes | 1 (5) | 3 (14) | 0.2765 |
| no | 18 (95) | 18 (86) | |
| Steatosis grade | 19 (100) | 14 (100) | |
| 2/3 | 1 (5) | 0 (0) | 0.5758 |
| 0/1 | 18 (95) | 14 (100) | |
| Metavir inflammation score | 18 (100) | 17 (100) | |
| 2/3 | 0 (0) | 1 (6) | 0.4857 |
| 0/1 | 18 (100) | 16 (94) | |
| Ishak fibrosis score | 19 (100) | 20 (100) | |
| 4/5/6 | 7 (37) | 8 (40) | 0.2525 |
| 0/1/2/3 | 12 (63) | 12 (60) | |
| Child-Pugh cirrhosis score | 19 (100) | 21 (100) | |
| B/C | 4 (21) | 6 (29) | 0.2481 |
| A | 15 (79) | 15 (71) | |
| CLIP score | 19 (100) | 21 (100) | |
| 4/5/6 | 2 (11) | 0 (0) | 0.2192 |
| 0/1/2/3 | 17 (89) | 21 (100) | |
| BCLC stage | 19 (100) | 21 (100) | |
| C/D | 3 (16) | 5 (24) | 0.2666 |
| A/B | 16 (84) | 16 (76) | |
| AJCC TNM stage | 19 (100) | 21 (100) | |
| IIIA/IIIB/IIIC/IVA/IVB | 4 (21) | 5 (24) | 0.2884 |
| I/II | 15 (79) | 16 (76) |
Notes: aOnly patients with available data were analyzed. bP-value was determined by the chi-square test. cThe density of PD-1-positive cells in tumor tissues above the median density (1.63) was defined as high density. dThe density of PD-L1-positive cells in tumor tissues above the median density (14.37) was defined as high density. eThere were no patients negative for HBsAg for analysis. ***P-value<0.001.
Abbreviations: HBV, hepatitis B virus; HCC, hepatocellular carcinoma; PD-1, programmed death 1; PD-L1, programmed death ligand 1; HBeAg, hepatitis B e antigen; AST, aspartate aminotransferase; ALT, alanine aminotransferase; AFP, alpha-fetoprotein; CLIP, Cancer of the Liver Italian Program; BCLC, Barcelona Clinic Liver Cancer; AJCC, American Joint Committee on Cancer; TNM, tumor-node-metastasis.